Repository logo
 
Publication

Diabetes mellitus therapy adherence and therapy characterization in Northeast Portugal: classical vs dipeptidyl peptidase iv (dpp-4) inhibitors

dc.contributor.authorPereira, Daniela S.M.
dc.contributor.authorSaldanha, Daniela
dc.contributor.authorPires, Sandra
dc.contributor.authorPinto, Isabel C.
dc.contributor.authorPereira, Olívia R.
dc.date.accessioned2017-06-05T13:24:17Z
dc.date.available2017-06-05T13:24:17Z
dc.date.issued2017
dc.description.abstractDiabetes mellitus is a chronic disease characterizes by the absence of insulin production by the body or the inability of their effectively use. Aim: To determine prevalence of diabetes types, the frequency of glycemic control, identify change in eating habits and physical activity, characterize the pharmacological therapy concerning classic and novel therapeutic approaches and verify the therapy adherence in diabetics of northeast Portugal. Methods: A cross-sectional study was performed by applying an interview to 202 adult diabetics of Trás-os-Montes region (Portugal), based on a questionnaire, with MAT scale (measure of adherence to therapy) validated for the Portuguese population. Results: The results showed 73,8% and 26,2% diabetics of type 2 and type 1, respectively. Most of the total diabetics (38,1%) have controlled the glycemic once a day, 60.4% have modified eating habits and 89.7% increased the frequency of physical activity. The drugs more used were metformin (63) and insulin (52) and the use of incretin mimetics was low (13.9%, 28), with more expression of the association of metformin and vildagliptin (21). The prevalence of diabetics adherents to therapy was 92,6%. Conclusions: The majority of diabetics adhered to pharmacological therapy and the use of dipeptidyl peptidase IV (DPP-4) inhibitors remains low.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationPereira, Daniela; Saldanha, Daniela; Pires, Sandra; Pinto, Isabel C.; Pereira, Olívia R. 82017) - Diabetes mellitus therapy adherence and therapy characterization in Northeast Portugal: classical vs dipeptidyl peptidase iv (dpp-4) inhibitors. Diabetes and Obesity International Journal. ISSN 2376-0494. 2:1, p. 1-6pt_PT
dc.identifier.issn2376-0494
dc.identifier.urihttp://hdl.handle.net/10198/14293
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMedwin Publisherspt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectDiabetes mellituspt_PT
dc.subjectTherapy adherencept_PT
dc.subjectDrugs therapypt_PT
dc.subjectMetforminpt_PT
dc.subjectDipeptidyl peptidase IV (DPP-4) inhibitorspt_PT
dc.titleDiabetes mellitus therapy adherence and therapy characterization in Northeast Portugal: classical vs dipeptidyl peptidase iv (dpp-4) inhibitorspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceTroy, MI, USApt_PT
oaire.citation.endPage6pt_PT
oaire.citation.issue2pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleDiabetes & Obesity International Journalpt_PT
oaire.citation.volumeS1pt_PT
person.familyNamePinto
person.familyNamePereira
person.givenNameIsabel C.
person.givenNameOlívia R.
person.identifier145216
person.identifier.ciencia-id851B-247F-C650
person.identifier.ciencia-idB312-AF21-D2FA
person.identifier.orcid0000-0003-4745-6489
person.identifier.orcid0000-0002-6275-3134
person.identifier.ridH-1049-2014
person.identifier.scopus-author-id52264387000
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication751d74ab-e27c-4713-97ba-62cad38d1890
relation.isAuthorOfPublicatione8fdab9a-3ad6-47e6-b90c-7a37aabcb453
relation.isAuthorOfPublication.latestForDiscoverye8fdab9a-3ad6-47e6-b90c-7a37aabcb453

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Diabetes Mellitus Therapy Adherence and Therapy Characterization in Northeast Portugal Classical Dipeptidyl Peptidase IV (DPP-4) Inhibitors.pdf
Size:
648.03 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: